Browsing Tag
Indian pharma
8 posts
Biocon goes all-in on biosimilars with $5.5bn Biocon Biologics merger and Viatris exit
Biocon to merge Biocon Biologics in $5.5B deal with full ownership via share swap and cash. Find out what it means for investors and global biosimilar strategy.
Novo Nordisk taps Emcure Pharmaceuticals to launch Poviztra in India as second brand of Wegovy
Novo Nordisk partners with Emcure Pharmaceuticals to launch Poviztra, a second brand of Wegovy, in India. Discover how this could reshape obesity treatment access.
Zydus Lifesciences stock edges higher as Sentynl faces FDA CRL for CUTX-101
Zydus Lifesciences’ U.S. unit Sentynl received an FDA Complete Response Letter for CUTX-101. Find out why investors remain optimistic despite regulatory delays.
Rubicon Research Rs 140cr pre-IPO boost: Can the pharma firm deliver sustained growth?
Rubicon Research secures ₹140 crore from TIMF Holdings and 360 ONE Funds ahead of IPO. Find out how the pharma player is positioning for growth.
Biologics race in Indian pharma: Can Glenmark’s AbbVie tie-up spark a broader innovation moment?
India’s biologics race heats up as Glenmark, Biocon, Sun Pharma, Dr. Reddy’s, and Lupin push beyond generics—see how each strategy stacks up.
Glenmark’s AbbVie deal: Can ISB 2001 make it India’s first true global biologics play?
Glenmark’s AbbVie deal for trispecific antibody ISB 2001 could redefine India’s role in global biologics—find out why this partnership matters now.
Glenmark Pharmaceuticals surges 10% after AbbVie licensing deal boosts ISB 2001 global reach
Glenmark Pharmaceuticals stock jumps 10% after announcing ISB 2001 licensing deal with AbbVie; find out what this could mean for its oncology ambitions.
Wanbury C RED expands nationwide: Can liposomal iron therapy transform India’s anemia treatment landscape?
Wanbury rolls out C RED across India, targeting anemia with liposomal iron tech. Doctors back its tolerability. Can it disrupt the iron supplement market?